NL301142I2 - Berotralstat en farmaceutisch aanvaardbare zouten daarvan - Google Patents
Berotralstat en farmaceutisch aanvaardbare zouten daarvanInfo
- Publication number
- NL301142I2 NL301142I2 NL301142C NL301142C NL301142I2 NL 301142 I2 NL301142 I2 NL 301142I2 NL 301142 C NL301142 C NL 301142C NL 301142 C NL301142 C NL 301142C NL 301142 I2 NL301142 I2 NL 301142I2
- Authority
- NL
- Netherlands
- Prior art keywords
- berotralstat
- pharmaceutically acceptable
- acceptable salts
- salts
- pharmaceutically
- Prior art date
Links
- UXNXMBYCBRBRFD-NDEPHWFRSA-N berotralstat Chemical compound NCC1=CC=CC(=C1)N1N=C(C=C1C(=O)NC1=C(F)C=CC(=C1)[C@@H](NCC1CC1)C1=CC(=CC=C1)C#N)C(F)(F)F UXNXMBYCBRBRFD-NDEPHWFRSA-N 0.000 title 1
- 229940121533 berotralstat Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461949808P | 2014-03-07 | 2014-03-07 | |
| US201461981515P | 2014-04-18 | 2014-04-18 | |
| PCT/US2015/019535 WO2015134998A1 (en) | 2014-03-07 | 2015-03-09 | Human plasma kallikrein inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL301142I1 NL301142I1 (enExample) | 2021-11-03 |
| NL301142I2 true NL301142I2 (nl) | 2021-12-09 |
Family
ID=54055948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL301142C NL301142I2 (nl) | 2014-03-07 | 2021-11-01 | Berotralstat en farmaceutisch aanvaardbare zouten daarvan |
Country Status (33)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2978751B1 (en) | 2013-03-25 | 2018-12-05 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| GB2517908A (en) | 2013-08-14 | 2015-03-11 | Kalvista Pharmaceuticals Ltd | Bicyclic inhibitors |
| NO2760821T3 (enExample) | 2014-01-31 | 2018-03-10 | ||
| UY35971A (es) | 2014-01-31 | 2015-07-31 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Macrociclos con grupos p2? aromáticos como inhibidores del factor xia |
| LT3828173T (lt) | 2014-03-07 | 2022-11-10 | Biocryst Pharmaceuticals, Inc. | Pakeistieji pirazolai kaip žmogaus plazmos kalikreino inhibitoriai |
| CN107074821B (zh) | 2014-09-04 | 2020-05-22 | 百时美施贵宝公司 | 为fxia抑制剂的二酰胺大环化合物 |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| KR102696432B1 (ko) * | 2015-10-01 | 2024-08-16 | 바이오크리스트파마슈티컬즈,인코포레이티드 | 인간 혈장 칼리크레인 저해제 |
| SG10201913616UA (en) | 2016-05-31 | 2020-03-30 | Kalvista Pharmaceuticals Ltd | Pyrazole derivatives as plasma kallikrein inhibitors |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201721515D0 (en) * | 2017-12-21 | 2018-02-07 | Kalvista Pharmaceuticals Ltd | Dosage forms comprising a plasma kallikrein inhibtor |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| MX2020005168A (es) | 2017-11-29 | 2020-08-20 | Kalvista Pharmaceuticals Ltd | Formas de dosificacion que contienen un inhibidor calicreina de plasma. |
| JP7538113B2 (ja) | 2018-08-20 | 2024-08-21 | アキリオン ファーマシューティカルズ，インコーポレーテッド | 補体ｄ因子の医学的障害の治療のための医薬化合物 |
| EP3846803A4 (en) | 2018-09-06 | 2022-08-10 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| AR116951A1 (es) * | 2018-11-02 | 2021-06-30 | Biocryst Pharm Inc | Sales cristalinas de un inhibidor de calicreína plasmática |
| EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| WO2020210368A1 (en) * | 2019-04-08 | 2020-10-15 | Biocryst Pharmaceuticals, Inc. | Plasma kallikrein inhibitors and methods of use thereof in ocular disorders |
| WO2021025969A1 (en) | 2019-08-02 | 2021-02-11 | Teva Pharmaceuticals International Gmbh | Solid state forms of berotralstat |
| BR112022002060A2 (pt) * | 2019-08-06 | 2022-06-07 | Biocryst Pharm Inc | Síntese de escala de processo de um inibidor de calicreína de plasma |
| WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| WO2021032935A1 (en) * | 2019-08-21 | 2021-02-25 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
| TW202144331A (zh) * | 2020-02-13 | 2021-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
| CN115362162A (zh) | 2020-02-20 | 2022-11-18 | 艾其林医药公司 | 用于治疗补体因子d介导的障碍的杂芳基化合物 |
| JP7245397B2 (ja) * | 2020-03-04 | 2023-03-23 | メッドシャイン ディスカバリー インコーポレイテッド | 複素環化合物 |
| CN115989224B (zh) * | 2020-06-16 | 2025-02-25 | 默沙东有限责任公司 | 血浆激肽释放酶抑制剂 |
| CN116157154A (zh) * | 2020-07-10 | 2023-05-23 | 默沙东有限责任公司 | 血浆激肽释放酶抑制剂 |
| WO2022060842A1 (en) * | 2020-09-15 | 2022-03-24 | The Trustees Of Columbia University In The City Of New York | Systems and methods for predicting graft dysfunction with exosome proteins |
| AU2022215844A1 (en) | 2021-02-02 | 2023-09-14 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
| CN116375648A (zh) * | 2023-03-22 | 2023-07-04 | 苏州农平科技发展有限公司 | 贝罗司他中间体的制备方法 |
| WO2025122555A1 (en) * | 2023-12-05 | 2025-06-12 | Valo Health, Inc. | S1p 1 receptor agonists and uses thereof |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| LU86084A1 (fr) | 1985-09-20 | 1987-04-02 | Faco Sa | Apparei de massage electrique |
| US5102417A (en) | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
| DE3633840A1 (de) | 1986-10-04 | 1988-04-14 | Hoechst Ag | Phenylpyrazolcarbonsaeurederivate, ihre herstellung und verwendung als pflanzenwachstumsregulatoren und safener |
| US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| WO1990013332A1 (en) | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Stent with sustained drug delivery |
| EP0470246B1 (en) | 1990-02-28 | 1995-06-28 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
| US5429634A (en) | 1993-09-09 | 1995-07-04 | Pdt Systems | Biogenic implant for drug delivery and method |
| US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
| US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
| US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| CN1246847A (zh) * | 1996-12-23 | 2000-03-08 | 杜邦药品公司 | 作为Xa因子抑制剂的含氮杂芳族化合物 |
| ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
| HUP0003906A2 (hu) * | 1997-06-19 | 2001-05-28 | Du Pont Pharmaceuticals Co. | Xa faktort gátló hatású heterociklusos vegyületek és ezeket tartalmazó gyógyszerkészítmények |
| US6339099B1 (en) * | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
| IL136637A0 (en) * | 1997-12-22 | 2001-06-14 | Du Pont Pharm Co | Nitrogen containing heteroaromatics with ortho-substituted pi's as factor xa inhibitors |
| US6271237B1 (en) * | 1997-12-22 | 2001-08-07 | Dupont Pharmaceuticals Company | Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors |
| US7015218B1 (en) * | 1999-02-10 | 2006-03-21 | Mitsubishi Pharma Corporation | Amide compounds and medicinal use thereof |
| CA2368630A1 (en) * | 1999-04-02 | 2000-10-12 | Ruth R. Wexler | Aryl sulfonyls as factor xa inhibitors |
| US20010044445A1 (en) | 1999-04-08 | 2001-11-22 | Bamaung Nwe Y. | Azole inhibitors of cytokine production |
| US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| US6329527B1 (en) | 1999-10-21 | 2001-12-11 | Bristol-Myers Squibb Pharma Company | Synthesis of 1,3,5-trisubstituted pyrazoles |
| AU2001273040A1 (en) * | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| BR0112297A (pt) | 2000-06-27 | 2003-05-06 | S A L V A T Lab Sa | Compostos carbamatos derivados de arilalquilaminas |
| HUP0500133A2 (hu) | 2000-09-22 | 2005-04-28 | Bristol-Myers Squibb Pharma Company | Hatékony eljárás Xa faktor inhibitorának előállítására |
| CZ20033003A3 (cs) | 2001-04-12 | 2004-05-12 | F@Áhoffmann@Laárocheáag | Dihydrobenzo [b][�Ź@]diazepin@onové deriváty jako MGLUR@ antagonisty II |
| EP1417200B1 (en) * | 2001-08-13 | 2010-06-02 | E.I. Du Pont De Nemours And Company | Substituted 1h-dihydropyrazoles, their preparation and use |
| TWI312274B (en) | 2001-08-13 | 2009-07-21 | Du Pont | Method for controlling particular insect pests by applying anthranilamide compounds |
| TW200724033A (en) | 2001-09-21 | 2007-07-01 | Du Pont | Anthranilamide arthropodicide treatment |
| CN1298706C (zh) * | 2001-09-21 | 2007-02-07 | 杜邦公司 | 杀虫二酰胺类 |
| US7030141B2 (en) * | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| TW200303309A (en) | 2001-12-04 | 2003-09-01 | Bristol Myers Squibb Co | Novel n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-trifluoromethyl)-1h-pyrazole-5-carboxamides as factor Xa inhibitors |
| TW200302225A (en) | 2001-12-04 | 2003-08-01 | Bristol Myers Squibb Co | Substituted amino methyl factor Xa inhibitors |
| WO2003099793A1 (en) | 2002-05-24 | 2003-12-04 | Takeda Pharmaceutical Company Limited | 1,2-azole derivatives with hypoglycemic and hypolipidemic activity |
| BR0311707A (pt) * | 2002-06-13 | 2005-03-15 | Du Pont | Composto, composição e método de controle de pelo menos uma praga invertebrada |
| DE10229070A1 (de) * | 2002-06-28 | 2004-01-15 | Merck Patent Gmbh | Phenylderivate 5 |
| US6770729B2 (en) | 2002-09-30 | 2004-08-03 | Medtronic Minimed, Inc. | Polymer compositions containing bioactive agents and methods for their use |
| WO2004078732A1 (fr) | 2003-01-28 | 2004-09-16 | Aventis Pharma S.A. | Produits n-aryl-heteroaromatiques, compositions les contenant et utilisation |
| CN102060806A (zh) | 2003-09-11 | 2011-05-18 | iTherX药品公司 | 细胞因子抑制剂 |
| WO2005094805A1 (ja) * | 2004-04-01 | 2005-10-13 | Institute Of Medicinal Molecular Design. Inc. | イミン誘導体及びアミド誘導体 |
| WO2005118552A2 (en) | 2004-04-13 | 2005-12-15 | E.I. Dupont De Nemours And Company | Anthranilamide insecticides |
| WO2005113522A1 (en) | 2004-05-07 | 2005-12-01 | Janssen Pharmaceutica, N.V. | Azole carboxamide inhibitors of bacterial type iii protein secretion systems |
| US20060069270A1 (en) | 2004-09-27 | 2006-03-30 | Rafael Shapiro | Process for the preparation of 1,3,5-trisubstituted pyrazoles via [3+2] cycloaddition |
| US7381732B2 (en) | 2004-10-26 | 2008-06-03 | Bristol-Myers Squibb Company | Pyrazolobenzamides and derivatives as factor Xa inhibitors |
| AU2005306363B2 (en) | 2004-11-18 | 2012-08-09 | E. I. Du Pont De Nemours And Company | Anthranilamide insecticides |
| CN101094829B (zh) * | 2004-12-07 | 2012-02-08 | 富山化学工业株式会社 | 新的氨茴酸衍生物或其盐 |
| US20070060589A1 (en) | 2004-12-21 | 2007-03-15 | Purandare Ashok V | Inhibitors of protein arginine methyl transferases |
| GB0516703D0 (en) | 2005-08-15 | 2005-09-21 | Syngenta Participations Ag | Novel insecticides |
| JP5186751B2 (ja) * | 2005-10-14 | 2013-04-24 | 住友化学株式会社 | ヒドラジド化合物およびその有害生物防除用途 |
| KR101315574B1 (ko) | 2005-10-14 | 2013-10-08 | 스미또모 가가꾸 가부시끼가이샤 | 히드라지드 화합물 및 이의 살충 용도 |
| DOP2006000234A (es) | 2005-10-28 | 2007-05-31 | Lilly Co Eli | Inhibidores de cinasa |
| US7897634B2 (en) | 2006-02-09 | 2011-03-01 | Athersys, Inc. | Pyrazoles for the treatment of obesity and other CNS disorders |
| EA200802210A1 (ru) * | 2006-05-16 | 2009-06-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Замещенные пролинамиды, их получение и их применение в качестве лекарственных средств |
| US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
| CN101495468A (zh) * | 2006-07-31 | 2009-07-29 | 艾克提弗赛特制药股份有限公司 | 血浆激肽释放酶抑制剂 |
| EP2051707B1 (en) | 2006-07-31 | 2013-07-17 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| US20120225057A1 (en) | 2006-10-11 | 2012-09-06 | Deciphera Pharmaceuticals, Llc | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases |
| CN101622244A (zh) * | 2006-11-03 | 2010-01-06 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| CN101679297B (zh) * | 2006-12-08 | 2012-01-11 | 埃克塞利希斯股份有限公司 | Lxr和fxr调节剂 |
| US8338437B2 (en) | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
| CN101298451B (zh) | 2007-04-30 | 2013-01-30 | 中国中化股份有限公司 | 苯甲酰胺类化合物及其应用 |
| WO2008134969A1 (fr) | 2007-04-30 | 2008-11-13 | Sinochem Corporation | Composés benzamides et leurs applications |
| CN102317279B (zh) | 2008-12-18 | 2015-03-04 | 拜尔农作物科学股份公司 | 作为杀虫剂的被四唑取代的邻氨基苯甲酰胺 |
| WO2010108733A1 (en) | 2009-03-26 | 2010-09-30 | Syngenta Participations Ag | Insecticidal compounds |
| US8946204B2 (en) | 2009-05-07 | 2015-02-03 | Gruenenthal Gmbh | Substituted phenylureas and phenylamides as vanilloid receptor ligands |
| SG181811A1 (en) | 2009-12-18 | 2012-07-30 | Activesite Pharmaceuticals Inc | Prodrugs of inhibitors of plasma kallikrein |
| CN102906090B (zh) | 2010-02-01 | 2015-06-24 | 癌症研究技术有限公司 | 1-(5-叔丁基-2-苯基-2h-吡唑-3-基)-3-[2-氟-4-(1-甲基-2-氧代-2,3-二氢-1h-咪唑并[4,5-b]吡啶-7-基氧基)-苯基]-脲和相关化合物及它们在治疗中的应用 |
| WO2011118818A1 (ja) | 2010-03-26 | 2011-09-29 | 味の素株式会社 | アミジノアニリン誘導体 |
| CN102285963B (zh) | 2010-06-21 | 2014-04-09 | 中国中化股份有限公司 | 3-甲氧基吡唑酰胺类化合物及其应用 |
| TW201211029A (en) | 2010-08-20 | 2012-03-16 | Gruenenthal Gmbh | Substituted cyclic carboxamide and urea derivatives as ligands of the vanilloid receptor |
| AR083817A1 (es) | 2010-11-10 | 2013-03-27 | Gruenenthal Gmbh | Derivados de carboxamida y urea heteroaromaticos sustituidos como ligandos del receptor vanilloide |
| US9284298B2 (en) | 2011-04-11 | 2016-03-15 | Nerviano Medical Sciences S.R.L. | Pyrazolyl-pyrimidine derivatives as kinase inhibitors |
| WO2012142308A1 (en) * | 2011-04-13 | 2012-10-18 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| WO2013036232A2 (en) | 2011-09-08 | 2013-03-14 | Deciphera Pharmaceuticals, Llc | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases |
| AR088799A1 (es) | 2011-11-09 | 2014-07-10 | Gruenenthal Gmbh | Derivados de carboxamida y urea a base de pirazolilos sustituidos que contienen una porcion fenilo sustituida con un grupo que contiene so₂ como ligandos del receptor de vanilloide |
| CN103467380B (zh) | 2013-09-29 | 2015-06-24 | 南开大学 | 一类取代苯基吡唑酰胺衍生物及其制备方法和应用 |
| LT3828173T (lt) | 2014-03-07 | 2022-11-10 | Biocryst Pharmaceuticals, Inc. | Pakeistieji pirazolai kaip žmogaus plazmos kalikreino inhibitoriai |
| AR116951A1 (es) | 2018-11-02 | 2021-06-30 | Biocryst Pharm Inc | Sales cristalinas de un inhibidor de calicreína plasmática |
| BR112022002060A2 (pt) | 2019-08-06 | 2022-06-07 | Biocryst Pharm Inc | Síntese de escala de processo de um inibidor de calicreína de plasma |
-
2015
- 2015-03-09 LT LTEP20191747.3T patent/LT3828173T/lt unknown
- 2015-03-09 RS RS20201483A patent/RS61159B1/sr unknown
- 2015-03-09 EP EP22191079.7A patent/EP4180424B1/en active Active
- 2015-03-09 CN CN202110045874.9A patent/CN113307772B/zh active Active
- 2015-03-09 AU AU2015226855A patent/AU2015226855C1/en active Active
- 2015-03-09 MA MA53399A patent/MA53399B1/fr unknown
- 2015-03-09 CA CA3164693A patent/CA3164693A1/en active Pending
- 2015-03-09 SM SM20210031T patent/SMT202100031T1/it unknown
- 2015-03-09 ES ES22191079T patent/ES3039514T3/es active Active
- 2015-03-09 CA CA2941380A patent/CA2941380C/en active Active
- 2015-03-09 SI SI201531442T patent/SI3113772T1/sl unknown
- 2015-03-09 CN CN201580022369.5A patent/CN106257976B/zh active Active
- 2015-03-09 HU HUE15759254A patent/HUE052668T2/hu unknown
- 2015-03-09 LT LTEP15759254.4T patent/LT3113772T/lt unknown
- 2015-03-09 RS RS20221083A patent/RS63763B1/sr unknown
- 2015-03-09 KR KR1020237008388A patent/KR102736869B1/ko active Active
- 2015-03-09 MY MYPI2016001634A patent/MY199131A/en unknown
- 2015-03-09 DK DK20191747.3T patent/DK3828173T3/da active
- 2015-03-09 EP EP15759254.4A patent/EP3113772B8/en active Active
- 2015-03-09 MX MX2020013059A patent/MX2020013059A/es unknown
- 2015-03-09 WO PCT/US2015/019535 patent/WO2015134998A1/en not_active Ceased
- 2015-03-09 MX MX2016011468A patent/MX377845B/es unknown
- 2015-03-09 SM SM20230002T patent/SMT202300002T1/it unknown
- 2015-03-09 ES ES15759254T patent/ES2836373T3/es active Active
- 2015-03-09 HR HRP20201916TT patent/HRP20201916T1/hr unknown
- 2015-03-09 KR KR1020167026786A patent/KR102510427B1/ko active Active
- 2015-03-09 IL IL280785A patent/IL280785B2/en unknown
- 2015-03-09 PT PT201917473T patent/PT3828173T/pt unknown
- 2015-03-09 PL PL20191747.3T patent/PL3828173T3/pl unknown
- 2015-03-09 DK DK15759254.4T patent/DK3113772T3/da active
- 2015-03-09 SG SG10202001795XA patent/SG10202001795XA/en unknown
- 2015-03-09 JP JP2016555752A patent/JP6574435B2/ja active Active
- 2015-03-09 HR HRP20221373TT patent/HRP20221373T1/hr unknown
- 2015-03-09 HU HUE20191747A patent/HUE060660T2/hu unknown
- 2015-03-09 EA EA201691803A patent/EA036251B1/ru unknown
- 2015-03-09 SG SG11201607267SA patent/SG11201607267SA/en unknown
- 2015-03-09 BR BR112016020199A patent/BR112016020199A8/pt not_active Application Discontinuation
- 2015-03-09 US US15/123,059 patent/US10125102B2/en active Active
- 2015-03-09 ES ES20191747T patent/ES2932406T3/es active Active
- 2015-03-09 PT PT157592544T patent/PT3113772T/pt unknown
- 2015-03-09 EP EP20191747.3A patent/EP3828173B1/en active Active
- 2015-03-09 NZ NZ724250A patent/NZ724250A/en unknown
- 2015-03-09 PH PH1/2016/501750A patent/PH12016501750B1/en unknown
- 2015-03-09 NZ NZ762034A patent/NZ762034A/en unknown
- 2015-03-09 PL PL15759254T patent/PL3113772T3/pl unknown
-
2016
- 2016-08-28 IL IL247518A patent/IL247518B/en active IP Right Grant
- 2016-09-13 ZA ZA2016/06320A patent/ZA201606320B/en unknown
-
2018
- 2018-05-11 US US15/977,129 patent/US10329260B2/en active Active
- 2018-06-15 US US16/009,943 patent/US10633345B2/en active Active
-
2019
- 2019-05-01 US US16/400,798 patent/US10689346B2/en active Active
- 2019-08-16 JP JP2019149385A patent/JP6915003B2/ja active Active
-
2020
- 2020-03-24 US US16/828,755 patent/US11192861B2/en active Active
- 2020-03-24 US US16/828,763 patent/US11203574B2/en active Active
- 2020-04-10 US US16/845,833 patent/US11230530B2/en active Active
- 2020-10-27 AU AU2020260400A patent/AU2020260400B2/en active Active
- 2020-12-08 CY CY20201101164T patent/CY1123810T1/el unknown
-
2021
- 2021-07-14 JP JP2021116716A patent/JP2021169499A/ja active Pending
- 2021-10-08 CY CY2021029C patent/CY2021029I2/el unknown
- 2021-10-14 LU LU00233C patent/LUC00233I2/fr unknown
- 2021-10-25 HU HUS2100045C patent/HUS2100045I1/hu unknown
- 2021-10-25 FR FR21C1048C patent/FR21C1048I2/fr active Active
- 2021-10-26 LT LTPA2021524C patent/LTC3113772I2/lt unknown
- 2021-11-01 NL NL301142C patent/NL301142I2/nl unknown
- 2021-11-09 US US17/522,065 patent/US11685721B2/en active Active
- 2021-11-15 US US17/526,377 patent/US11708332B2/en active Active
- 2021-12-07 US US17/543,929 patent/US11708333B2/en active Active
-
2022
- 2022-10-25 AU AU2022259742A patent/AU2022259742B2/en active Active
- 2022-11-07 NO NO2022046C patent/NO2022046I1/no unknown
-
2023
- 2023-04-18 US US18/136,016 patent/US12162838B2/en active Active
- 2023-04-18 US US18/136,025 patent/US12116346B2/en active Active
- 2023-11-06 JP JP2023189564A patent/JP2023181543A/ja active Pending
-
2024
- 2024-09-24 US US18/894,797 patent/US20250257040A1/en active Pending
- 2024-10-11 US US18/913,643 patent/US20250270171A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2022046I1 (no) | Berotralstat and pharmaceutically acceptable salts thereof | |
| NL301217I2 (nl) | tirzepatide en farmaceutisch aanvaardbare zouten daarvan | |
| NO2025015I1 (no) | Repotrectinib and/or pharmaceutically acceptable salts and esters thereof | |
| NO2025038I1 (no) | Risdiplam or a pharmaceutically acceptable salt thereof - forlenget | |
| NO2025045I1 (no) | Elafibranor and pharmaceutically acceptable salts and esters thereof | |
| NL301094I2 (nl) | Avapritinib en farmaceutisch aanvaardbare zouten daarvan | |
| NO2022058I1 (no) | Capmatinib or a pharmaceutically acceptable salt thereof | |
| EP3285633A4 (en) | STEERING MICROENDOSCOPE | |
| MA40933A (fr) | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines | |
| LT3204359T (lt) | Tetrahidroizochinolino dariniai | |
| HRP20190432T1 (hr) | Spojevi pladienolid piridina i postupci uporabe | |
| HUE048321T2 (hu) | Karabazol származékok | |
| DK3203834T3 (da) | Hovbehandlingsarrangement | |
| DK3199161T3 (da) | Farmaceutisk præparat | |
| DK3231803T3 (da) | Dihydroindolizinonderivat | |
| DK3131898T3 (da) | Fluoroalkylfluorenderivativer | |
| LT3247711T (lt) | Naujos scy-078 druskos ir polimorfai | |
| DK3498588T3 (da) | Holdearrangement | |
| DK3191148T3 (da) | Lægemiddelindretninger med reduceret thrombogenicitet | |
| HUE058726T2 (hu) | Új nilotinib sók és azok polimorfjai | |
| EP4233950C0 (en) | NASAL ADMINISTRATION | |
| LT3097076T (lt) | Nauji cip-eikozanoidų dariniai | |
| PL3125964T3 (pl) | Środki antykoncepcyjne i pokrewne | |
| HUE050881T2 (hu) | Gyógyszerkészítmény | |
| IL252908A0 (en) | Fumagillol derivatives |